Form 4: Labcorp EVP Sells Shares Under Pre-Arranged Plan

Labcorp's EVP of Corporate Affairs, Sandra D. van der Vaart, sold 547.5397 shares of common stock for $284.91 per share on February 27, 2026, under a Rule 10b5-1 plan.

Summary

• Sandra D. van der Vaart, Executive Vice President of Corporate Affairs at Labcorp Holdings Inc. (LH), reported a sale of common stock.
• The transaction involved the disposition of 547.5397 shares of common stock.
• The shares were sold at a price of $284.91 per share.
• The transaction date for the sale was February 27, 2026.
• Following this transaction, Ms. van der Vaart beneficially owns 2,578.9467 shares of Labcorp common stock.
• The sale was conducted pursuant to a Rule 10b5-1 trading plan, indicating a pre-arranged transaction.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine insider transaction under a pre-arranged plan, which typically does not signal a change in company fundamentals or management's confidence.

Positives

• The transaction was executed under a Rule 10b5-1 plan, which indicates a pre-scheduled sale rather than an opportunistic one, often mitigating concerns about insider selling.

Negatives

• An executive sold a portion of their holdings, which could be interpreted as a lack of confidence, though this is largely mitigated by the pre-arranged Rule 10b5-1 plan.

Risks

• NA

Future Outlook

NA

Management Comments

• NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales under Rule 10b5-1 plans, are common practice for executives to manage personal finances and diversify holdings without necessarily implying a negative outlook on the company's future. In the healthcare diagnostics industry, such routine transactions are generally not seen as indicative of operational performance or strategic shifts.

Comparison to Industry Standards

• Insider sales under Rule 10b5-1 plans are standard practice across all industries for executives managing personal liquidity and portfolio diversification.
• The volume of shares sold by Ms. van der Vaart is relatively small compared to the company's total outstanding shares, consistent with typical executive stock management rather than a significant divestment that might raise concerns.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: The sale represents a minor dilution effect, but the volume is insignificant relative to the company's market capitalization. The 10b5-1 plan mitigates concerns about opportunistic selling.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• NA

Key Dates

Keywords

Labcorp, LH, insider trading, Form 4, stock sale, executive compensation, Rule 10b5-1, Sandra D. van der Vaart